Dexcom (DXCM) Non Operating Interest Expenses (2010 - 2023)

Dexcom (DXCM) has reported Non Operating Interest Expenses for 14 consecutive years, with $5.9 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Non Operating Interest Expenses rose 25.53% year-over-year to $5.9 million in Q2 2023; TTM through Jun 2023 was $19.8 million, a 6.45% increase from a year earlier, with the FY2022 full-year figure at $18.6 million, down 1.06% from the prior year.
• Non Operating Interest Expenses was $5.9 million for Q2 2023 at Dexcom, up from $4.6 million in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $24.4 million in Q3 2020 and troughed at -$42.4 million in Q4 2020.
• A 5-year average of $7.0 million and a median of $4.8 million in 2021 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses jumped 212.5% in 2019 and slumped 377.12% in 2020, its largest moves.
• Over 5 years, Non Operating Interest Expenses stood at $15.3 million in 2019, then tumbled by 377.12% to -$42.4 million in 2020, then surged by 111.08% to $4.7 million in 2021, then changed by 0.0% to $4.7 million in 2022, then gained by 25.53% to $5.9 million in 2023.
• The last three Non Operating Interest Expenses figures came in at $5.9 million (Q2 2023), $4.6 million (Q1 2023), and $4.7 million (Q4 2022), per Business Quant data.